Votexetine ممکن است به اولین داروی شناخت درمانی افسردگی در اروپا تبدیل شود

The new indications of the antidepressant drug Brintellix of Lingbei pharmaceutical have been supported by CHMP. This drug will soon become the first antidepressant approved in the EU to improve the cognitive function of patients with depression. The new indications are based on the results of the connecting test. The results show that when compared with placebo, vortioxetine and Lilly's antidepressant competitive product duloxetine can better improve various cognitive indexes of patients.

People with severe depression usually report a series of cognitive symptoms, including obvious difficulties in thinking, attention, and memory of new information, which can damage patients' self-confidence and lead to social disharmony. Although cognitive problems have been well recognized in other mental diseases such as schizophrenia, there are few studies on their impact on depression.

پدرسن، مدیر تحقیق و توسعه Lingbei گفت: ما خوشحالیم که vortioxetine نظرات مثبتی را از CHMP دریافت کرد، به ویژه وضعیت اختلال شناختی در تأثیرگذاری بر نتیجه درمان اکثر بیماران. داده‌های دلگرم‌کننده‌ای که در رسیدگی به اختلالات شناختی دیده‌ایم، ما را به این باور می‌رساند که ورتیوکستین این پتانسیل را دارد که به بسیاری از بیماران در درمان افسردگی خود کمک کند.

Votexetine has been listed in the United States for only more than a year, and it is gradually lifted in the whole EU. Last September, it was listed in Denmark, Lingbei's hometown. It is reported that this drug is the fastest-growing new antidepressant in the United States in the past three years. This drug is jointly listed by Lingbei and Takeda in the United States.

این خبر خوبی برای Lingbei است، زیرا به داروهای جدید نیاز دارد تا تأثیرات ناشی از انقضای حق ثبت اختراع داروی ضد افسردگی قدیمی Idprem را جبران کند. Yidepulum یک داروی پرفروش با فروش سالانه چندین میلیارد دلاری بود که تحت تأثیر رقابت داروهای ژنریک قرار گرفته است.

Votexetine sold 188 million kroner (27 million) in six EU markets last year, compared with 83 million kroner in the fourth quarter alone, so it still has some ways to catch up with Idem. Although Idprem no longer has a market franchise, it still sold 4.6 billion kroner. The Danish company also has long-acting schizophrenic drug aripiprazole and an alcohol addiction treatment drug nalmefene, which can help vortioxetine increase the company's revenue again.